Silexion Therapeutics Corp (SLXN) completed a 1-for-10 reverse share split of its ordinary shares, effective after the close of trading on May 28, 2026. The primary purpose of the reverse share split is to maintain compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market. As a result of the split, the number of issued and outstanding ordinary shares decreased by a 1-for-10 ratio, and the par value per share increased from $0.0135 to $0.135. The company's authorized share capital remains at $796,500, now consisting of 5,900,000 ordinary shares, down from 59,000,000. Warrants exercisable for ordinary shares were also adjusted: each pre-split warrant now entitles the holder to 1/10th of an ordinary share, and the exercise price increased ten-fold to $15,525.00 per post-Reverse Share Split ordinary share. Fractional shares resulting from warrant exercises will be rounded up to the nearest whole number of ordinary shares at the broker level. Ordinary shares began trading on a split-adjusted basis on the Nasdaq Capital Market under the existing ticker symbol SLXN at market open on May 29, 2026.